BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35489606)

  • 21. Potential role of Bacillus Calmette-Guérin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects.
    Charoenlap S; Piromsopa K; Charoenlap C
    Asian Pac J Allergy Immunol; 2020 Sep; 38(3):150-161. PubMed ID: 32686943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at Risk.
    Tsilika M; Taks E; Dolianitis K; Kotsaki A; Leventogiannis K; Damoulari C; Kostoula M; Paneta M; Adamis G; Papanikolaou I; Stamatelopoulos K; Bolanou A; Katsaros K; Delavinia C; Perdios I; Pandi A; Tsiakos K; Proios N; Kalogianni E; Delis I; Skliros E; Akinosoglou K; Perdikouli A; Poulakou G; Milionis H; Athanassopoulou E; Kalpaki E; Efstratiou L; Perraki V; Papadopoulos A; Netea MG; Giamarellos-Bourboulis EJ
    Front Immunol; 2022; 13():873067. PubMed ID: 35865520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial).
    Pittet LF; Messina NL; Gardiner K; Orsini F; Abruzzo V; Bannister S; Bonten M; Campbell JL; Croda J; Dalcolmo M; Elia S; Germano S; Goodall C; Gwee A; Jamieson T; Jardim B; Kollmann TR; Guimarães Lacerda MV; Lee KJ; Legge D; Lucas M; Lynn DJ; McDonald E; Manning L; Munns CF; Perrett KP; Prat Aymerich C; Richmond P; Shann F; Sudbury E; Villanueva P; Wood NJ; Lieschke K; Subbarao K; Davidson A; Curtis N;
    BMJ Open; 2021 Oct; 11(10):e052101. PubMed ID: 34711598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers.
    Rivas MN; Ebinger JE; Wu M; Sun N; Braun J; Sobhani K; Van Eyk JE; Cheng S; Arditi M
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33211672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.
    Tomita Y; Sato R; Ikeda T; Sakagami T
    Vaccine; 2020 Sep; 38(41):6352-6356. PubMed ID: 32863070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic.
    Aspatwar A; Gong W; Wang S; Wu X; Parkkila S
    Int Rev Immunol; 2022; 41(2):283-296. PubMed ID: 33960271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are BCG-induced non-specific effects adequate to provide protection against COVID-19?
    Vashishtha VM
    Hum Vaccin Immunother; 2021 Jan; 17(1):88-91. PubMed ID: 32762516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.
    Ręka G; Korzeniowska A; Piecewicz-Szczęsna H
    Przegl Epidemiol; 2020; 74(2):290-302. PubMed ID: 33115218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial.
    Pittet LF; Moore CL; McDonald E; Barry S; Bonten M; Campbell J; Croda J; Dalcolmo M; Davidson A; Douglas MW; Gardiner K; Gwee A; Jardim B; Lacerda MVG; Lucas M; Lynn DJ; Manning L; de Oliveira RD; Perrett KP; Prat-Aymerich C; Richmond PC; Rocha JL; Rodriguez-Baño J; Warris A; Wood NJ; Messina NL; Curtis N;
    EClinicalMedicine; 2023 Oct; 64():102203. PubMed ID: 37719417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Chrissian AA; Oyoyo UE; Patel P; Lawrence Beeson W; Loo LK; Tavakoli S; Dubov A
    Vaccine; 2022 May; 40(23):3174-3181. PubMed ID: 35465979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study.
    Blossey AM; Brückner S; May M; Parzmair GP; Sharma H; Shaligram U; Grode L; Kaufmann SHE; Netea MG; Schindler C
    Clin Infect Dis; 2023 Apr; 76(7):1304-1310. PubMed ID: 36358012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trained Immunity, BCG and SARS-CoV-2 General Outline and Possible Management in COVID-19.
    Zapolnik P; Kmiecik W; Mazur A; Czajka H
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence similarity of HSP65 of Mycobacterium bovis BCG with SARS-CoV-2 spike and nuclear proteins: may it predict an antigen-dependent immune protection of BCG against COVID-19?
    Finotti P
    Cell Stress Chaperones; 2022 Jan; 27(1):37-43. PubMed ID: 34755305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Bacillus Calmette-Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial.
    Sinha S; Ajayababu A; Thukral H; Gupta S; Guha SK; Basu A; Gupta G; Thakur P; Lingaiah R; Das BK; Singh UB; Singh R; Narang R; Bhowmik D; Wig N; Modak DC; Bandyopadhyay B; Chakrabarty B; Kapoor A; Tewari S; Prasad N; Hashim Z; Nath A; Kumari N; Goswami R; Pandey S; Pandey RM
    Infect Dis Ther; 2022 Dec; 11(6):2205-2217. PubMed ID: 36242739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare Workers (HCWs) and non-HCWs reaction to Bacillus Calmette-Guérin (BCG) in the BATTLE trial.
    Jalalizadeh M; Leme PAF; Buosi K; Dionato FAV; Dal Col LSB; Giacomelli CF; Reis LO
    Vaccine; 2023 Oct; 41(44):6599-6606. PubMed ID: 37743116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2.
    Glisic S; Perovic VR; Sencanski M; Paessler S; Veljkovic V
    J Proteome Res; 2020 Nov; 19(11):4649-4654. PubMed ID: 32794723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents.
    Gong W; Mao Y; Li Y; Qi Y
    Int Immunopharmacol; 2022 Jul; 108():108870. PubMed ID: 35597119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers.
    Søvik WLM; Madsen AMR; Aaby P; Nielsen S; Benn CS; Schaltz-Buchholzer F
    Vaccine; 2024 Mar; 42(8):1966-1972. PubMed ID: 38378387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Maltezou HC; Panagopoulos P; Sourri F; Giannouchos TV; Raftopoulos V; Gamaletsou MN; Karapanou A; Koukou DM; Koutsidou A; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Sipsas NV; Hatzigeorgiou D
    Vaccine; 2021 Nov; 39(48):7021-7027. PubMed ID: 34740473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.